Concerns over misuse of 'Wigobi'... Obesity Society states it should only be used by obese patients

These days, it's the Hugo Bee issue.

I heard that it is known to be effective for weight loss, so many people are seeking it.

VigoBee is a weight loss medication, so it is not recommended to take it artificially for cosmetic purposes.

There are also many illegal distribution and transactions.

Since there are many side effects, it's best to consult with a doctor before using it.

 

 

 

Since the launch of the obesity treatment drug 'Wegovy' in Korea, concerns about misuse due to illegal online distribution have increased. The Korean Society of Obesity issued a statement on the 23rd urging health authorities to actively regulate its use within the approved scope.

 

On this day, the Korean Society of Obesity welcomed the release of WigoBi, known as an effective drug at a time when obesity has become a serious social issue, but also expressed concern that misuse has become a reality, such as the circulation and trading for cosmetic purposes immediately after its release.

The association pointed out that "Wigobi is a medication developed for the treatment of obese patients and is a prescription drug that requires a doctor's prescription," and that "the treatment target is clearly defined based on body mass index (BMI)."

 

The Ministry of Health and Welfare and the Ministry of Food and Drug Safety urged to reduce the misuse of incretin-based drugs like Wegovy and to ensure that the public can receive prescriptions safely, emphasizing the importance of adhering to the approved indications for these medications and urging doctors and the public to use them only for eligible obese patients.

 

He repeatedly emphasized that indiscriminate use of VicoBi can cause side effects and urged that it be used under the guidance and monitoring of a physician.

 

The society warned, "Wegovy shows excellent weight loss effects, but it can also cause various side effects such as nausea, vomiting, constipation, diarrhea, abdominal bloating, aspiration pneumonia, and pancreatitis," and added, "When used for cosmetic purposes rather than obesity treatment, patients may experience side effects rather than therapeutic benefits."

 

Meanwhile, he added, "The obesity treatments previously released in Korea have been used for cosmetic purposes or illegally distributed online," and "To reduce misuse, we must thoroughly crack down on illegal distribution and actively monitor side effects."

 

VigoBi is an anti-obesity medication that acts on the glucagon-like peptide-1 (GLP-1) receptor. It slows gastric motility and suppresses appetite by acting on the central nervous system, resulting in weight loss.

 

It was officially launched domestically on the 15th of this month.

 

Prescriptions can be made for obese patients with a BMI of 30 or higher, or for overweight patients with a BMI between 27 and 30 who also have hypertension, dyslipidemia, or other related conditions.

 

<Source: JoongAng Ilbo>